The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.
The effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment peri...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2003
|
| _version_ | 1797069794401320960 |
|---|---|
| author | Soedamah-Muthu, S Colhoun, H Thomason, M Betteridge, D Durrington, P Hitman, G Fuller, J Julier, K Mackness, M Neil, H |
| author_facet | Soedamah-Muthu, S Colhoun, H Thomason, M Betteridge, D Durrington, P Hitman, G Fuller, J Julier, K Mackness, M Neil, H |
| author_sort | Soedamah-Muthu, S |
| collection | OXFORD |
| description | The effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment period of atorvastatin 10 mg vs. placebo in 122 men and women. All subjects had type 2 diabetes and a modest dyslipidaemia (mean LDL-cholesterol 3.2 mmol/l and median triglycerides 1.8 mmol/l) and had a previous myocardial infarction. Compared with placebo, atorvastatin therapy was associated with a greater decrease in medium VLDL (median within person change -13.4 vs. -5.9 nmol/l, P<0.001 adjusted for baseline level), small VLDL (median change -17.8 vs. -8.1 nmol/l, P=0.002), large LDL (mean within person change -167.9 vs. -48.6 nmol/l, P<0.001) and medium LDL (median within person change -101.8 vs. -22.3 nmol/l, P=0.017). Atorvastatin therapy was also associated with a greater increase in large HDL than placebo (median change 1.40 vs. 0.80 micromol/l, P=0.02) and there was little change in small HDL so that average HDL particle size increased significantly with atorvastatin (P=0.04). In addition to reducing levels of (enzymatically measured) triglyceride, LDL-cholesterol and apolipoprotein B in diabetic patients, atorvastatin significantly reduces NMR measured medium and small VLDL and large and medium LDL, and increases large HDL. |
| first_indexed | 2024-03-06T22:29:43Z |
| format | Journal article |
| id | oxford-uuid:57e2656c-2777-4879-aace-28f3dcae1410 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:29:43Z |
| publishDate | 2003 |
| record_format | dspace |
| spelling | oxford-uuid:57e2656c-2777-4879-aace-28f3dcae14102022-03-26T16:59:26ZThe effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:57e2656c-2777-4879-aace-28f3dcae1410EnglishSymplectic Elements at Oxford2003Soedamah-Muthu, SColhoun, HThomason, MBetteridge, DDurrington, PHitman, GFuller, JJulier, KMackness, MNeil, HThe effect of statin therapy on subclasses of LDL, VLDL and HDL lipoproteins is unclear. We compared changes in serum lipids, apolipoproteins and nuclear magnetic resonance (NMR) spectroscopy measured lipoprotein subclass concentration and average particle size over a minimum 6 months treatment period of atorvastatin 10 mg vs. placebo in 122 men and women. All subjects had type 2 diabetes and a modest dyslipidaemia (mean LDL-cholesterol 3.2 mmol/l and median triglycerides 1.8 mmol/l) and had a previous myocardial infarction. Compared with placebo, atorvastatin therapy was associated with a greater decrease in medium VLDL (median within person change -13.4 vs. -5.9 nmol/l, P<0.001 adjusted for baseline level), small VLDL (median change -17.8 vs. -8.1 nmol/l, P=0.002), large LDL (mean within person change -167.9 vs. -48.6 nmol/l, P<0.001) and medium LDL (median within person change -101.8 vs. -22.3 nmol/l, P=0.017). Atorvastatin therapy was also associated with a greater increase in large HDL than placebo (median change 1.40 vs. 0.80 micromol/l, P=0.02) and there was little change in small HDL so that average HDL particle size increased significantly with atorvastatin (P=0.04). In addition to reducing levels of (enzymatically measured) triglyceride, LDL-cholesterol and apolipoprotein B in diabetic patients, atorvastatin significantly reduces NMR measured medium and small VLDL and large and medium LDL, and increases large HDL. |
| spellingShingle | Soedamah-Muthu, S Colhoun, H Thomason, M Betteridge, D Durrington, P Hitman, G Fuller, J Julier, K Mackness, M Neil, H The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title | The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title_full | The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title_fullStr | The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title_full_unstemmed | The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title_short | The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. |
| title_sort | effect of atorvastatin on serum lipids lipoproteins and nmr spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease |
| work_keys_str_mv | AT soedamahmuthus theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT colhounh theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT thomasonm theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT betteridged theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT durringtonp theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT hitmang theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT fullerj theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT julierk theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT macknessm theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT neilh theeffectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT soedamahmuthus effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT colhounh effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT thomasonm effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT betteridged effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT durringtonp effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT hitmang effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT fullerj effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT julierk effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT macknessm effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease AT neilh effectofatorvastatinonserumlipidslipoproteinsandnmrspectroscopydefinedlipoproteinsubclassesintype2diabeticpatientswithischaemicheartdisease |